244 related articles for article (PubMed ID: 32631835)
1. EmPHasis-10 health-related quality of life score predicts outcomes in patients with idiopathic and connective tissue disease-associated pulmonary arterial hypertension: results from a UK multicentre study.
Lewis RA; Armstrong I; Bergbaum C; Brewis MJ; Cannon J; Charalampopoulos A; Church AC; Coghlan JG; Davies RJ; Dimopoulos K; Elliot C; Gibbs JSR; Gin-Sing W; Haji G; Hameed AG; Howard LS; Johnson MK; Kempny A; Kiely DG; Lo Giudice F; McCabe C; Peacock AJ; Peleyeju O; Pepke-Zaba J; Polwarth G; Price L; Sabroe I; Schreiber BE; Sheares K; Taboada D; Thompson AAR; Toshner MR; Wanjiku I; Wort SJ; Yorke J; Condliffe R
Eur Respir J; 2021 Feb; 57(2):. PubMed ID: 32631835
[TBL] [Abstract][Full Text] [Related]
2. Long-term outcomes of domiciliary intravenous iloprost in idiopathic and connective tissue disease-associated pulmonary arterial hypertension.
Ramjug S; Hussain N; Hurdman J; Elliot CA; Sabroe I; Armstrong IJ; Billings C; Hamilton N; Kiely DG; Condliffe R
Respirology; 2017 Feb; 22(2):372-377. PubMed ID: 27651181
[TBL] [Abstract][Full Text] [Related]
3. Cross-cultural validation of the Chinese version of the EmPHasis-10 questionnaire in connective tissue disease patients with pulmonary arterial hypertension and its relationship with risk stratification.
Shi Y; Dong X; Hu X; Weng L; Liu Y; Lai J; Tian Z; Zhao J; Li M; Peng J; Wang Q; Zeng X
BMC Pulm Med; 2022 Jul; 22(1):264. PubMed ID: 35790938
[TBL] [Abstract][Full Text] [Related]
4. Pulmonary capillary endothelial metabolic dysfunction: severity in pulmonary arterial hypertension related to connective tissue disease versus idiopathic pulmonary arterial hypertension.
Langleben D; Orfanos SE; Giovinazzo M; Hirsch A; Baron M; Senécal JL; Armaganidis A; Catravas JD
Arthritis Rheum; 2008 Apr; 58(4):1156-64. PubMed ID: 18383374
[TBL] [Abstract][Full Text] [Related]
5. Anticoagulation in pulmonary arterial hypertension - association with mortality, healthcare utilization, and quality of life: The Pulmonary Hypertension Association Registry (PHAR).
Garry JD; Kolaitis NA; Kronmal R; Thenappan T; Hemnes A; Grinnan D; Bull T; Chakinala MM; Horn E; Simon MA; De Marco T;
J Heart Lung Transplant; 2022 Dec; 41(12):1808-1818. PubMed ID: 36150996
[TBL] [Abstract][Full Text] [Related]
6. Comparison of Treatment Response in Idiopathic and Connective Tissue Disease-associated Pulmonary Arterial Hypertension.
Rhee RL; Gabler NB; Sangani S; Praestgaard A; Merkel PA; Kawut SM
Am J Respir Crit Care Med; 2015 Nov; 192(9):1111-7. PubMed ID: 26291092
[TBL] [Abstract][Full Text] [Related]
7. Early risk prediction in idiopathic
Hjalmarsson C; Kjellström B; Jansson K; Nisell M; Kylhammar D; Kavianipour M; Rådegran G; Söderberg S; Wikström G; Wuttge DM; Hesselstrand R
ERJ Open Res; 2021 Jul; 7(3):. PubMed ID: 34350280
[TBL] [Abstract][Full Text] [Related]
8. Methamphetamine-associated pulmonary arterial hypertension: data from the national biological sample and data repository for pulmonary arterial hypertension (PAH Biobank).
Charoenpong P; Dhillon N; Murnane K; Goeders N; Hall N; Keller C; Bhuiyan MAN; Walter R
BMJ Open Respir Res; 2023 Dec; 10(1):. PubMed ID: 38061804
[TBL] [Abstract][Full Text] [Related]
9. 10-year survival of pulmonary arterial hypertension associated with connective tissue disease: insights from a multicentre PAH registry.
Chen X; Quan R; Qian Y; Yang Z; Yu Z; Zhang C; Yang Y; Zhang G; Shen J; Wang Q; Gu Q; Xiong C; Jing X; Han H; He J
Rheumatology (Oxford); 2023 Nov; 62(11):3555-3564. PubMed ID: 36912696
[TBL] [Abstract][Full Text] [Related]
10. Maximal Exercise Testing Using the Incremental Shuttle Walking Test Can Be Used to Risk-Stratify Patients with Pulmonary Arterial Hypertension.
Lewis RA; Billings CG; Hurdman JA; Smith IA; Austin M; Armstrong IJ; Middleton J; Rothman AMK; Harrington J; Hamilton N; Hameed AG; Thompson AAR; Charalampopoulos A; Elliot CA; Lawrie A; Sabroe I; Wild JM; Swift AJ; Condliffe R; Kiely DG
Ann Am Thorac Soc; 2021 Jan; 18(1):34-43. PubMed ID: 32926635
[No Abstract] [Full Text] [Related]
11. The cost-effectiveness of bosentan in the United Kingdom for patients with pulmonary arterial hypertension of WHO functional class III.
Stevenson MD; Macdonald FC; Langley J; Hunsche E; Akehurst R
Value Health; 2009; 12(8):1100-5. PubMed ID: 19558373
[TBL] [Abstract][Full Text] [Related]
12. Exercise pathophysiology differs between connective tissue diseases-associated pulmonary arterial hypertension and idiopathic pulmonary arterial hypertension.
Zhang Y; Jin Q; Zhao Z; Zhao Q; Yu X; Yan L; Li X; An C; Ma X; Xiong C; Luo Q; Liu Z
Clin Exp Rheumatol; 2021; 39(5):1063-1070. PubMed ID: 33200733
[TBL] [Abstract][Full Text] [Related]
13. Mortality and prognostic factors in connective tissue disease-associated pulmonary arterial hypertension patients complicated with right heart failure.
Deng X; Jiang N; Huang C; Zhou S; Peng L; Zhang L; Liu J; Wang L; Zhou J; Wang Q; Weng L; Peng J; Zhao J; Li M; Zeng X
Int J Rheum Dis; 2023 May; 26(5):862-869. PubMed ID: 36892249
[TBL] [Abstract][Full Text] [Related]
14. Simplified risk stratification for pulmonary arterial hypertension associated with connective tissue disease.
Li X; Sun X; Huang Y; Wang Y; Yang X; Wang J; Zhang N; Gu L; Zhang M; Wang Q
Clin Rheumatol; 2019 Dec; 38(12):3619-3626. PubMed ID: 31385084
[TBL] [Abstract][Full Text] [Related]
15. Ambrisentan response in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH) - A subgroup analysis of the ARIES-E clinical trial.
Fischer A; Denton CP; Matucci-Cerinic M; Gillies H; Blair C; Tislow J; Nathan SD
Respir Med; 2016 Aug; 117():254-63. PubMed ID: 27492539
[TBL] [Abstract][Full Text] [Related]
16. Physical Activity and Its Association with Traditional Outcome Measures in Pulmonary Arterial Hypertension.
Minhas J; Shou H; Hershman S; Zamanian R; Ventetuolo CE; Bull TM; Hemnes A; Chakinala MM; Mathai S; Al-Naamani N; Ellenberg S; Matura LA; Kawut SM; Shcherbina A
Ann Am Thorac Soc; 2022 Apr; 19(4):572-582. PubMed ID: 34473938
[No Abstract] [Full Text] [Related]
17. Metabolomic Differences in Connective Tissue Disease-Associated Versus Idiopathic Pulmonary Arterial Hypertension in the PVDOMICS Cohort.
Simpson CE; Hemnes AR; Griffiths M; Grunig G; Tang WHW; Garcia JGN; Barnard J; Comhair SA; Damico RL; Mathai SC; Hassoun PM;
Arthritis Rheumatol; 2023 Dec; 75(12):2240-2251. PubMed ID: 37335853
[TBL] [Abstract][Full Text] [Related]
18. Macitentan in Pulmonary Arterial Hypertension Associated with Connective Tissue Disease (CTD-PAH): Real-World Evidence from the Combined OPUS/OrPHeUS Dataset.
Channick R; Chin KM; McLaughlin VV; Lammi MR; Zamanian RT; Turricchia S; Ong R; Mitchell L; Kim NH
Cardiol Ther; 2024 Jun; 13(2):315-339. PubMed ID: 38451426
[TBL] [Abstract][Full Text] [Related]
19. Idiopathic and connective tissue disease-associated pulmonary arterial hypertension (PAH): Similarities, differences and the role of autoimmunity.
Favoino E; Prete M; Liakouli V; Leone P; Sisto A; Navarini L; Vomero M; Ciccia F; Ruscitti P; Racanelli V; Giacomelli R; Perosa F
Autoimmun Rev; 2024 Apr; 23(4):103514. PubMed ID: 38181859
[TBL] [Abstract][Full Text] [Related]
20. Predictors of mortality in connective tissue disease-associated pulmonary arterial hypertension: a cohort study.
Ngian GS; Stevens W; Prior D; Gabbay E; Roddy J; Tran A; Minson R; Hill C; Chow K; Sahhar J; Proudman S; Nikpour M
Arthritis Res Ther; 2012 Oct; 14(5):R213. PubMed ID: 23039366
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
